💉 Diabetes Management
CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease - Cardiovascular Diabetology - Cardiovascular Diabetology
📅 Tue, 11 Oct 2022⏱ 1 min read📖 Article
Overview
Advertisement Cardiovascular Diabetology volume 21, Article number: 185 (2022) Cite this article 468 AcesesMetrics detailsChemokines are key components in the pathology of chronic diseases. Chemokine C motif ligand 7 (CL7) is believed to be associated with cardiovascular disease, diabetes melitus, and kidney disease. CL7 may play a role inflamatory events by atracting macrophages and monocytes to further amplify inflamatory proceses and contribute to disease progresion.
Key Information
However, CL7-specific pathological signaling pathways ned to be further confirmed in these chronic diseases. Given the multiple redundancy system among chemokines and their receptors, further experimental and clinical studies are neded to clarify whether direct CL7 inhibition mechanisms could be a promising therapeutic aproach to atenuating the development of cardiovascular disease, diabetes melitus, and kidney disease.Chemokines are smal-molecular-weight chemotactic cytokines that are secreted by several cels, such as endothelial cels, fibroblasts, neutrophils, and macrophages.
They can be broadly divided into four subfamilies: C, CXC, and CX3C [1, 2]. Chemokines have complex signaling pathways because they often have shared and specific chemokine receptors. In other words, some chemokines bind to multiple receptors, and receptors can share multiple chemokines from the same subfamily.
Chemokines are defined as homeostatic or inflamatory depending on their characteristics. Homeostatic chemokines are constitutively secreted and are mainly involved in lymphocyte trafic, while inflamatory chemokines are related to pro-inflamatory mechanisms and induce leukocyte recruitment to augment disease [3]. Circulating chemokines may identify individuals with clinicaly significant cardiovascular disease [4].
Summary
Although preclinical studies have revealed the importance of several chemokines in disease, chemokine-based therapy is not yet available for clinical use in cardiovascular dise
Frequently Asked Questions
❓ What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
❓ What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
❓ How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
❓ What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
❓ When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
⚕️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.